Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment

The combination of lopinavir/ritonavir remains one of the first-line therapies for the initial antiretroviral regimen in pediatric HIV-infected children. However, the implementation of this recommendation has faced many challenges due to cold-chain requirements, high alcohol content, and unpalatabil...

Descripción completa

Detalles Bibliográficos
Autores: Malebari, Azizah M., Kara, Aytug, Khayyat, Ahdab N., Mohammad, Khadijah A., Serrano López, Dolores Remedios
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/72526
Acceso en línea:https://hdl.handle.net/20.500.14352/72526
Access Level:acceso abierto
Palabra clave:pediatric formulation
ritonavir
lopinavir
minitablet
3D printing
direct powder extrusion
HIV
FDM
HME
Inmunología
Pediatría
Farmacología (Farmacia)
2412 Inmunología
3201.10 Pediatría
3209 Farmacología
id ES_e42eea7df60c4f4e0a19b2b590f8e2a2
oai_identifier_str oai:docta.ucm.es:20.500.14352/72526
network_acronym_str ES
network_name_str España
repository_id_str
spelling Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV TreatmentMalebari, Azizah M.Kara, AytugKhayyat, Ahdab N.Mohammad, Khadijah A.Serrano López, Dolores Remediospediatric formulationritonavirlopinavirminitablet3D printingdirect powder extrusionHIVFDMHMEInmunologíaPediatríaFarmacología (Farmacia)2412 Inmunología3201.10 Pediatría3209 FarmacologíaThe combination of lopinavir/ritonavir remains one of the first-line therapies for the initial antiretroviral regimen in pediatric HIV-infected children. However, the implementation of this recommendation has faced many challenges due to cold-chain requirements, high alcohol content, and unpalatability for ritonavir-boosted lopinavir syrup. In addition, the administration of crushed tablets has shown a detriment for the oral bioavailability of both drugs. Therefore, there is a clinical need to develop safer and better formulations adapted to children’s needs. This work has demonstrated, for the first time, the feasibility of using direct powder extrusion 3D printing to manufacture personalized pediatric HIV dosage forms based on 6 mm spherical tablets. H-bonding between drugs and excipients (hydroxypropyl methylcellulose and polyethylene glycol) resulted in the formation of amorphous solid dispersions with a zero-order sustained release profile, opposite to the commercially available formulation Kaletra, which exhibited marked drug precipitation at the intestinal pH.MPDIUniversidad Complutense de Madrid20222022-03-3120222022-03-31journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/72526reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/725262026-06-02T12:44:21Z
dc.title.none.fl_str_mv Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
title Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
spellingShingle Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
Malebari, Azizah M.
pediatric formulation
ritonavir
lopinavir
minitablet
3D printing
direct powder extrusion
HIV
FDM
HME
Inmunología
Pediatría
Farmacología (Farmacia)
2412 Inmunología
3201.10 Pediatría
3209 Farmacología
title_short Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
title_full Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
title_fullStr Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
title_full_unstemmed Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
title_sort Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
dc.creator.none.fl_str_mv Malebari, Azizah M.
Kara, Aytug
Khayyat, Ahdab N.
Mohammad, Khadijah A.
Serrano López, Dolores Remedios
author Malebari, Azizah M.
author_facet Malebari, Azizah M.
Kara, Aytug
Khayyat, Ahdab N.
Mohammad, Khadijah A.
Serrano López, Dolores Remedios
author_role author
author2 Kara, Aytug
Khayyat, Ahdab N.
Mohammad, Khadijah A.
Serrano López, Dolores Remedios
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv pediatric formulation
ritonavir
lopinavir
minitablet
3D printing
direct powder extrusion
HIV
FDM
HME
Inmunología
Pediatría
Farmacología (Farmacia)
2412 Inmunología
3201.10 Pediatría
3209 Farmacología
topic pediatric formulation
ritonavir
lopinavir
minitablet
3D printing
direct powder extrusion
HIV
FDM
HME
Inmunología
Pediatría
Farmacología (Farmacia)
2412 Inmunología
3201.10 Pediatría
3209 Farmacología
description The combination of lopinavir/ritonavir remains one of the first-line therapies for the initial antiretroviral regimen in pediatric HIV-infected children. However, the implementation of this recommendation has faced many challenges due to cold-chain requirements, high alcohol content, and unpalatability for ritonavir-boosted lopinavir syrup. In addition, the administration of crushed tablets has shown a detriment for the oral bioavailability of both drugs. Therefore, there is a clinical need to develop safer and better formulations adapted to children’s needs. This work has demonstrated, for the first time, the feasibility of using direct powder extrusion 3D printing to manufacture personalized pediatric HIV dosage forms based on 6 mm spherical tablets. H-bonding between drugs and excipients (hydroxypropyl methylcellulose and polyethylene glycol) resulted in the formation of amorphous solid dispersions with a zero-order sustained release profile, opposite to the commercially available formulation Kaletra, which exhibited marked drug precipitation at the intestinal pH.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-03-31
2022
2022-03-31
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/72526
url https://hdl.handle.net/20.500.14352/72526
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 3.0 España
https://creativecommons.org/licenses/by/3.0/es/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 3.0 España
https://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MPDI
publisher.none.fl_str_mv MPDI
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422568340979712
score 15,300724

Similares en LA Referencia